Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Phase 1 Completed 24 enrolled Jiangsu HengRui Medicine Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

Timeline

Start: 2020-05-20
Primary completion: 2020-12-27
Completion: 2020-12-30

Publications

Mai J, Lin H, Wu M, Wang D, Zhang H, Jin Q, Chen C. Pharmacokinetics and safety of SHR0302, a selective JAK1 inhibitor, in Chinese patients with hepatic impairment. Front Pharmacol. 2026 Jul 2;17:1857187. doi: 10.3389/fphar.2026.1857187. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR0302	Unknown	8 mg	Oral

Indications

No indication recorded.